Hutchmed spikes after cancer trial win despite 2024 revenue miss
Source: SeekingAlpha
2025-03-19 13:36:40 ET
More on HUTCHMED, Innovent, etc.
- HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript
- HUTCHMED (China) Limited 2024 Q4 - Results - Earnings Call Presentation
- Despite A Promising Future For Hutchmed, We Have Concerns About Development Of The Share Price (Rating Downgrade)
- Innovent wins second China nod for Nuvation-partnered cancer therapy
- Chinese regulators accept NDA for Orpathys/Tagrisso combo
Read the full article on Seeking Alpha
For further details see:
Hutchmed spikes after cancer trial win despite 2024 revenue miss
HUTCHMED (China)
NASDAQ: HMDCF
HMDCF Trading
0.0% G/L:
$2.996 Last:
165 Volume:
$2.996 Open:
HMDCF Latest News
HMDCF Stock Data
$2,597,321,277
104,485,926
2.8%
28
N/A
Pharmaceuticals
Healthcare
HK
Hong Kong
